Tesofensine for Weight Loss: Dosage, Benefits, and Results

Tesofensine is a research compound studied for body weight in clinical trials. It stands out from most weight-focused peptides because it is not a GLP-1 agonist at all. It works upstream in the brain on three neurotransmitters at once, which is why people search for tesofensine dosage ranges that differ sharply from semaglutide or tirzepatide.

This page covers the dose ladder used in trials, the 0.5 mg figure that anchored the strongest data, and the vial math you need before you handle any compound. It is educational only. Tesofensine is not approved for human consumption, and dosing decisions belong to a licensed clinician.

How tesofensine works: the triple-monoamine angle

Tesofensine is a triple monoamine reuptake inhibitor. It slows the reabsorption of three brain chemicals: noradrenaline, dopamine, and serotonin. By keeping more of each in circulation, trials reported reduced appetite signaling. This is a different lever than the gut-hormone pathway that GLP-1 drugs pull, so the numbers do not transfer.

That mechanism also explains why trial doses are tiny. We are talking fractions of a milligram, not the multi-milligram weekly doses common with tirzepatide or semaglutide. A small absolute amount changes the math completely once you reconstitute.

The tesofensine dose ladder from trials

Phase 2 research, most notably the TIPO-1 trial, tested several daily oral amounts. The commonly cited ladder looks like this:

• 0.25 mg per day, the lowest studied step
• 0.5 mg per day, the dose most often described as the sweet spot
• 1.0 mg per day, a higher step that showed more frequent side effects in trial reports

The 0.5 mg figure draws the most attention because it produced the clearest signal in trials while keeping reported tolerability issues lower than the 1.0 mg arm. Researchers often describe it as the balance point on the ladder. Higher is not automatically better here, and the 1.0 mg step is where reports of elevated heart rate and mood changes clustered.

Tesofensine vial math: a worked example

Many research vials of tesofensine list a total amount in milligrams. To turn that into a per-dose volume, you need the concentration after mixing. Here is the general approach using round numbers.

1. Read the total in the vial, for example 10 mg of powder.
2. Pick a mixing volume, for example 2 mL of liquid. That gives a concentration of 10 mg divided by 2 mL, which is 5 mg/mL.
3. Convert your target reference amount to volume. For a 0.5 mg reference, divide 0.5 mg by 5 mg/mL, which is 0.1 mL.
4. On a U-100 insulin syringe, 0.1 mL equals 10 units.

Change the mixing volume and every number shifts. Add 1 mL instead of 2 mL and concentration becomes 10 mg/mL, so the same 0.5 mg reference now sits at 0.05 mL, or 5 units. The reconstitution calculator handles this so you are not doing fraction math by hand, and the mg to units converter turns any milliliter figure into syringe units.

If the milligram-to-microgram step trips you up, the mcg to mg conversion guide walks through it. For the mixing step itself, the how to reconstitute peptides guide covers neutral lab handling.

What trials reported on results and tolerability

In Phase 2 research, the 0.5 mg arm showed the most discussed body-weight changes over roughly six months, with the 0.25 mg arm lower and the 1.0 mg arm higher but less tolerated. Reported side effects across the ladder included dry mouth, faster heart rate, sleep changes, and shifts in mood. The monoamine mechanism is the likely reason the cardiovascular and mood signals appear, since the same chemicals affect heart rate and sleep.

None of this is an outcome promise. Trial averages are not individual results, and this compound is not approved. Anyone weighing it should review the full picture with a licensed clinician.

Where tesofensine sits among research compounds

Tesofensine is one of several non-GLP-1 directions in the weight-research space. If you are comparing options, the peptides library lists the major compounds with their own calculators and reference pages. For the GLP-1 side of the comparison, semaglutide vs tirzepatide lays out how those two differ, and retatrutide vs tirzepatide covers a newer triple-agonist that is a different molecule entirely from tesofensine.

The takeaway: tesofensine runs on a sub-milligram ladder, the 0.5 mg step anchored the strongest trial data, and the math is unforgiving at that scale. Get the concentration right first, then defer every dosing decision to a professional. See the disclaimer for the full research-use framing.